Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GenFleet Therapeutics (Shanghai) Inc.
勁方醫藥科技(上海)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2595)

SHARE REPURCHASE

SHARE REPURCHASE

The board of directors (the "**Board**") of GenFleet Therapeutics (Shanghai) Inc. (the "**Company**") hereby announces that on November 6, 2026, pursuant to the repurchase mandate (the "**Repurchase Mandate**") granted at the annual general meeting of the Company held on May 11, 2026, the Company repurchased (the "**Share Repurchase**"), on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), 220,000 H shares of the Company (the "**H Shares**"), representing approximately 0.058% of the Company's total issued shares (excluding treasury shares) immediately prior to the Share Repurchase. The highest repurchase price per H Share was HK$22.78 and the lowest repurchase price per H Share was HK$21.68, and an aggregate amount of HK$4,860,732 (excluding transaction fees) was utilized by the Company for the Share Repurchase on November 6, 2026.

LISTING RULES IMPLICATIONS

Pursuant to Rule 10.06(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), the repurchase price for the Share Repurchase should not be at or above HK$22.5078 per H Share (the "**Price Limit**"), being 5% higher than the average closing market price of the H Shares for the five trading days immediately preceding the date of the Share Repurchase.

When placing the relevant orders, the executing team inadvertently set the purchase price for certain H Shares at an amount above the Price Limit. As a result, 60,000 H Shares, representing approximately 27.27% of the total number of H Shares repurchased on November 6, 2026, were repurchased at prices ranging from HK$22.60

to HK$22.78 per H Share, exceeding the Price Limit by HK$0.0922 to HK$0.2722 per H Share (the "**Non-compliance Incident**"). The Company acknowledged that the Non-compliance Incident breached Rule 10.06(2)(a) of the Listing Rules.

REMEDIAL ACTIONS

The Company sincerely regrets its non-compliance with the Listing Rules. Nonetheless, the Company would like to stress that such non-compliance was inadvertent and unintentional. To prevent such incident from occurring again, the Company has implemented the following remedial measures to further strengthen internal control and ensure full compliance with the Listing Rules for future share repurchase(s):

(i) the Company has revised its operational procedures to ensure dual-level verification by designated personnel from the Office of President and the Investment Management Department prior to placing any order, and the designated personnel from the Investment Management Department will place purchase orders with the broker after completing such verification; and

(ii) the Company has arranged a training session on regulatory compliance matters relating to Chapter 10 of the Listing Rules, for its Directors, senior management and the responsible personnel to reinforce their understanding of and the importance of compliance with the Listing Rules and mitigate the risk of recurrence.

Going forward, the Company will ensure strict compliance with the Listing Rules.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, November 8, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive Directors; (ii) Mr. ZHU Jingyang as non-executive Director; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive Directors.